CBLL (NASDAQ: CBLL) insider filing shows proposed 39,000-share sale and prior disposals
A Form 144 filing for Ceribell, Inc. (CBLL) indicates a proposed sale of 39,000 shares of common stock. The filing also details several past transactions, including completed sales of 39,000, 2,084, and 39,000 shares, with associated cash values, and references stock option exercises. The insider-affiliated holder, Xingjuan Chao, is noted in connection with these transactions.
CBLL Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Ceribell Inc (CBLL). It indicates a current "Buy" technical sentiment based on an aggregation of 10 technical signals, with 6 flashing buy and 4 indicating sell. The analysis details key indicators like RSI, MACD, support and resistance levels, and various moving averages to assess the stock's short-term momentum and long-term trend.
CBLL Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of Ceribell Inc (CBLL), detailing its revenue breakdown, profitability margins, and a comparison with competitors. CBLL generates most of its revenue from EEG headbands, showcasing a strong gross margin but negative operating and net margins, indicating operational inefficiencies. The company's financial performance is benchmarked against industry peers like CSTL and AVNS to provide context.
Insider Selling: CeriBell (NASDAQ:CBLL) CTO Sells 11,112 Shares of Stock
CeriBell (NASDAQ:CBLL) CTO Raymond Woo sold 11,112 shares of the company's stock on April 1st for $18.56 per share, totaling $206,238.72, reducing his ownership by 6.24%. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan, with previous sales in March and February. The stock trades around $18.57, and analysts currently have a "Moderate Buy" rating with an average price target of $24.67.
Raymond Woo, Ceribell CTO, sells $206k in CBLL stock
Raymond Woo, CTO of Ceribell Inc. (NASDAQ:CBLL), sold 11,112 shares for approximately $206,243 on April 1, 2026. This sale followed a significant 47% stock surge, although investingPro data suggests the stock is currently overvalued. Simultaneously, Woo exercised options to acquire 11,112 shares and received an additional 30,736 restricted stock units.
Raymond Woo, Ceribell CTO, sells $206k in CBLL stock
Raymond Woo, CTO of Ceribell, Inc. (NASDAQ:CBLL), sold 11,112 shares for approximately $206,243 after acquiring shares through option exercises and restricted stock units. This transaction follows a 47% stock surge and occurred alongside news of Ceribell receiving FDA Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection monitor, highlighting the company's innovation in medical technology.
Ceribell (CBLL) CTO exercises options, sells 11,112 shares and gets new grants
Ceribell, Inc. (CBLL) Chief Technology Officer Raymond Woo exercised stock options for 11,112 shares and subsequently sold them in open-market transactions for approximately $18.53–$18.58 per share. These actions were conducted under a Rule 10b5-1 trading plan. Additionally, Woo received new grants including 51,227 stock options and 30,736 restricted stock units, bringing his direct common stock holdings to 197,648 shares.
Ceribell (CBLL) CFO receives stock options and RSU equity awards
Ceribell, Inc.'s CFO, Scott Blumberg, reported the acquisition of equity compensation awards through a Form 4 filing. He received a stock option for 51,227 shares at an exercise price of $18.50 per share, expiring in 2036, and a grant of 30,736 restricted stock units. These awards are service-based and increase his direct common stock holdings to 149,070 shares.
Ceribell (CBLL) CRO granted stock options and RSU awards
Ceribell, Inc. (CBLL) Chief Revenue Officer Joseph S. Manni was granted stock options to purchase 51,227 shares at $18.50 per share, expiring in 2036, and 30,736 restricted stock units (RSUs) on April 1, 2026. These compensation awards vest quarterly starting May 20, 2026, contingent on his continued employment. Following these transactions, Manni directly holds 57,669 shares of common stock.
Ceribell (CBLL) finance chief receives stock options and 22,050 RSUs
Ceribell, Inc.'s Senior VP of Finance and Principal Accounting Officer, David Foehr, has been granted 36,750 stock options with an exercise price of $18.50 per share and 22,050 restricted stock units (RSUs). These compensation awards, granted on April 1, 2026, are subject to vesting schedules tied to his continued employment. Following these grants, Foehr directly holds 39,600 shares of common stock, in addition to the newly granted options and RSUs.
CBLL (NASDAQ: CBLL) Form 144 shows insider sales and option resales
CBLL (Ceribell, Inc.) filed a Form 144, indicating proposed resales of common shares stemming from option grants in 2021 and 2023. The filing details proposed sales of 1,472 and 9,640 shares on April 1, 2026. Additionally, the document discloses previous open-market sales by Raymond Woo in early 2026, totaling over 33,000 shares across several transactions with specific gross proceeds.
Protara, Ceribell rise on FDA breakthrough designations
This article mentions that Protara Therapeutics and Ceribell have received FDA breakthrough designations. This news has led to increases in their respective stock values or company valuations. The content of the article is not provided, but the title suggests positive regulatory developments for both companies.
CeriBell, Inc. (NASDAQ:CBLL) Receives Average Recommendation of "Moderate Buy" from Brokerages
CeriBell, Inc. (NASDAQ:CBLL) has received a "Moderate Buy" consensus from seven brokerages, with an average 12-month price target of $24.67, and some firms reiterating higher targets of $30. Despite beating earnings and revenue estimates this quarter, the company remains unprofitable with a negative net margin and ROE. Insiders have sold a significant number of shares recently, though they still hold over 20% of the company's stock.
Ceribell (CBLL) CEO exercises stock options, now holds 766,792 shares
Ceribell, Inc. President and CEO Chao Xingjuan exercised stock options to acquire 55,628 shares of common stock at exercise prices of $2.24 and $3.65 per share. Following these transactions, she directly holds 766,792 shares of CBLL common stock. An additional 369,088 shares are held indirectly by the ACP 2021 Trust, where she serves as co-trustee.
Ceribell, Inc. honors Alex Purcell with Citizens Award for leadership in training initiatives
Ceribell, Inc. has recognized Alex Purcell, Associate Director of Training, with the Ceribell Citizens Award for his leadership in empowering new hires and setting high standards. This award highlights Purcell's contributions to the company's commitment to excellence and professional development by challenging employees to exceed expectations. The recognition is part of Ceribell's broader focus on nurturing talent and fostering a culture of achievement, as seen in previous awards for individual contributions.
CBLL PE Ratio & Valuation, Is CBLL Overvalued
Ceribell Inc (CBLL) is currently in the "Fair zone" according to relative valuation, with its forward P/S ratio of 7.45 considered fair compared to its five-year average. The fair price for CBLL is estimated between $9.83 and $23.57. While its P/S ratio is significantly above the industry average, robust revenue growth suggests this premium may be sustainable.
CeriBell, Inc. (NASDAQ:CBLL) Short Interest Update
CeriBell, Inc. (NASDAQ:CBLL) experienced a 16% increase in short interest as of February 27th, totaling 1,925,021 shares, which represents about 6.4% of outstanding shares. Despite recent insider sales by the CTO and CFO, insiders still hold approximately 20.10% of the company. The company holds a "Moderate Buy" consensus analyst rating with an average target price of $24.67 and recently surpassed quarterly earnings and revenue estimates.
Suma receives Ceribell, Inc. accolade for breakthrough neonatal care innovation
Ceribell, Inc. awarded Senior Machine Learning Engineer Suma with the Ceribell Citizens Award for her significant contributions to neonatal monitoring, including the development of a unique solution and multiple academic submissions. This recognition highlights Ceribell's commitment to research-driven healthcare advancements and its ongoing focus on integrating AI into critical care solutions. While details of the new solution remain undisclosed, the company continues its trajectory in AI-driven neonatal care.
Director at Ceribell (CBLL) sells 827 shares via Rule 10b5-1 plan
Ceribell, Inc. director Rebecca B. Robertson sold 827 shares of common stock at $17.80 per share through an open-market transaction. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, Robertson directly holds 18,749 shares of the company's common stock.
Ceribell’s Woo sells $202k in shares
Ceribell's Chief Technology Officer, Raymond Woo, sold 11,112 shares for over $202,000 but also acquired the same number through option exercises. This comes as Ceribell's stock has gained 42% in six months, with analysts suggesting it may be overvalued despite a recent FDA Breakthrough Device Designation and a maintained Buy rating from BTIG. The company is actively engaged in strategic and operational developments, including lease extensions and board changes.
Foehr David, senior VP at Ceribell, sells $81k in CBLL stock
David Foehr, Senior VP at Ceribell, Inc. (CBLL), sold 4,560 shares of common stock for $81,168 on March 3, 2026, while also exercising options to acquire an equal number of shares for $21,432. The sale occurred amid a weekly stock decline but six-month gain, with InvestingPro indicating CBLL is currently overvalued. This transaction was part of a pre-arranged Rule 10b5-1 trading plan.
CBLL (NASDAQ: CBLL) affiliate Xingjuan Chao sells multiple blocks totaling 145,084 shares
An affiliate of CBLL, Xingjuan Chao, reported multiple sales of company shares totaling 145,084 shares through Form 144 filings. These transactions occurred between December 2025 and February 2026, generating over $2.9 million in proceeds for the seller. The filing also outlines planned option-related sales and grants for various future dates.
Ceribell (CBLL) finance VP exercises options, sells 4,560 shares under 10b5-1 plan
David Foehr, Senior VP of Finance and PAO at Ceribell (CBLL), exercised stock options for 4,560 shares and subsequently sold the same number of shares at $17.80 each on March 3, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in September 2025. After these sales, Foehr directly holds 17,550 shares of Ceribell common stock.
CeriBell (NASDAQ:CBLL) Director Rebecca Robertson Sells 827 Shares
CeriBell (NASDAQ:CBLL) Director Rebecca Robertson sold 827 shares of company stock on March 3rd at an average price of $17.80, reducing her stake by 4.22%. Following the transaction, she directly owns 18,749 shares valued at approximately $333,732. The company recently reported quarterly earnings that beat analyst estimates for both EPS and revenue, though it maintains negative net margin and return on equity.
CeriBell (NASDAQ:CBLL) CEO Sells $680,550.00 in Stock
CeriBell CEO Xingjuan Chao recently sold 39,000 shares of company stock for $680,550, reducing his ownership by 5.20%. This transaction follows two other insider sales earlier in the year, totaling approximately $2.40 million from 120,084 shares. Despite these sales, CeriBell analysts maintain a "Moderate Buy" rating with an average price target of $24.67, and the company recently surpassed quarterly EPS and revenue estimates.
David Foehr Sells 4,560 Shares of CeriBell (NASDAQ:CBLL) Stock
David Foehr, VP of CeriBell (NASDAQ:CBLL), sold 4,560 shares of the company's stock for $81,168 on March 3rd, reducing his stake by over 20%. This sale is part of a pattern of selling by Foehr this year, totaling 17,022 shares across five transactions. CeriBell recently reported better-than-expected quarterly earnings and holds a "Moderate Buy" consensus rating from analysts with a target price of $24.67.
Ceribell CEO Chao sells $680k in CBLL stock
Ceribell CEO Chao Xingjuan sold 39,000 shares of CBLL stock for approximately $680,564 on March 3, 2026, as part of a pre-arranged trading plan. Despite the stock's recent decline, it remains up 51% over six months but is considered overvalued by InvestingPro. Chao also acquired 25,000 shares through option exercises, and the company recently received Breakthrough Device Designation for its stroke detection monitor and had a "Buy" rating reiterated by BTIG.
Robertson sells Ceribell (CBLL) shares worth $14,720
Director Rebecca Robertson sold 827 shares of Ceribell, Inc. (NASDAQ:CBLL) for $14,720 on March 3, 2026, under a Rule 10b5-1 trading plan. This transaction occurred amidst a weekly stock decline, though shares are up significantly over six months. The company recently received FDA Breakthrough Device Designation for its LVO stroke detection monitor and BTIG reiterated a Buy rating with a $30 price target.
Foehr David, senior VP at Ceribell, sells $81k in CBLL stock
David Foehr, Senior VP at Ceribell, sold 4,560 shares of CBLL stock for $81,168 and simultaneously exercised options to acquire the same number of shares for $21,432. These transactions, executed under a Rule 10b5-1 plan, come as the stock has seen recent fluctuations but remains up significantly over the past six months. In other news, Ceribell received FDA Breakthrough Device Designation for an LVO stroke detection monitor and extended office leases, while BTIG reiterated a Buy rating with a $30.00 price target.
Ceribell Earnings Call Highlights Strong Growth, Rising Costs
Ceribell reported strong Q4 2025 revenue of $24.8 million, up 34% year-over-year, and full-year revenue of $89.1 million, up 36%, driven by robust product and subscription sales. Despite premium gross margins of 87-88%, the company faced rising operating expenses, tariff impacts, and legal spending, leading to a wider net loss of $53.4 million for 2025. Ceribell expanded its total addressable market to over $3.5 billion through regulatory wins and new indications, guiding to 25-29% revenue growth for 2026 while maintaining a strong cash position for future investments.
Ceribell CTO exercises options, sells 11,112 shares | CBLL SEC Filing - Form 4
Ceribell, Inc. CTO Raymond Woo exercised multiple stock options and subsequently sold 11,112 shares of common stock on March 2, 2026. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted in May 2025. Following these sales, Woo directly holds 166,912 shares of Ceribell common stock, with sales occurring at weighted-average prices between $18.10 and $18.41 per share.
CeriBell (NASDAQ:CBLL) CTO Sells $147,587.75 in Stock
CeriBell (NASDAQ:CBLL) CTO Raymond Woo sold 8,087 shares of the company's stock on March 2nd for $147,587.75, reducing his stake by 4.62%. This follows other share sales in February and January. Despite the sales, analysts maintain a "Moderate Buy" rating for CBLL with an average price target of $24.67, even though the company reported negative profitability and analysts expect a full-year EPS of -$2.46.
Ceribell (CBLL) CEO sells 39,000 shares and exercises options
Ceribell, Inc. (CBLL) President and CEO Xingjuan Chao recently exercised stock options and sold 39,000 common shares under a Rule 10b5-1 trading plan. The sales occurred on March 3, 2026, at weighted average prices between $17.45–$17.46 per share. Following these transactions, Ms. Chao directly holds 711,164 shares and has indirect exposure to an additional 369,088 shares through the ACP 2021 Trust.
CeriBell, Inc. (NASDAQ:CBLL) Given Average Rating of "Moderate Buy" by Analysts
CeriBell, Inc. (NASDAQ:CBLL) has received a "Moderate Buy" consensus rating from seven analysts, with an average 12-month price target of $24.67. Despite the positive analyst outlook, company insiders have been net sellers, offloading approximately $6.43 million worth of shares in the last 90 days, though they still retain a significant 20.1% ownership. The healthcare technology company recently exceeded quarterly revenue and EPS expectations but remains unprofitable, with its shares currently trading around $18.08.
Cautious Guidance Offsets Solid Q4 for CeriBell, Inc. (CBLL), Says Canaccord
Canaccord maintained a Buy rating on CeriBell, Inc. (CBLL) but reduced its price target from $30 to $28, citing cautious guidance despite a strong Q4 2025 earnings beat and several upcoming growth drivers. CeriBell reported a 34% increase in Q4 sales to $24.8 million and a 36% rise in total 2025 revenue to $89.1 million, fueled by organic growth and new accounts. The company, which specializes in rapid EEG solutions, anticipates $111 million to $115 million in sales for 2026 and has secured several FDA clearances.
Cautious Guidance Offsets Solid Q4 for CeriBell, Inc. (CBLL), Says Canaccord
CeriBell, Inc. (CBLL) delivered a strong fourth quarter in 2025 with a 34% increase in sales to $24.8 million, driven by growth in both new and existing accounts. Despite solid results, including $89.1 million in total income for the year, Canaccord lowered its price target from $30 to $28 while maintaining a Buy rating, citing cautious guidance from management. The company, which specializes in rapid EEG solutions, anticipates 2026 sales between $111 million and $115 million and recently secured several FDA clearances.
Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
Ceribell reported strong financial results for Q4 and full year 2025, with total revenue increasing by 34% and 36% respectively, driven by account expansion and adoption. The company also achieved significant regulatory milestones, including FDA clearances for continuous monitoring, seizure detection in neonates, and Breakthrough Device Designation for stroke detection, positioning them for continued growth and market expansion. Ceribell projects 2026 revenue to be between $111 million and $115 million.
CeriBell, Inc. (CBLL) Stock Analysis: Exploring a 43% Potential Upside in the Innovative Medical Devices Sector
CeriBell, Inc. (CBLL) is an innovative medical technology company specializing in advanced EEG systems for neurological diagnostics. Despite some financial challenges, the company's flagship Ceribell System, enhanced by AI, and strong analyst buy ratings with a target price range indicating a potential 43.67% upside, make it an attractive investment for growth-focused individuals. CeriBell's focus on digital health solutions and strategic investments could lead to significant long-term returns.
Analysts Offer Insights on Healthcare Companies: Ceribell, Inc. (CBLL) and Option Care Health (OPCH)
Two healthcare companies, Ceribell, Inc. (CBLL) and Option Care Health (OPCH), recently received bullish sentiments from analysts. Bank of America Securities maintained a Buy rating on Ceribell with a $29.00 average price target, while Bank of America Securities and Morgan Stanley maintained Buy ratings on Option Care Health, with a price target consensus of $39.50. These recommendations suggest optimistic outlooks for both companies within the Healthcare sector.
[Form 4] Ceribell, Inc. Insider Trading Activity
Ceribell, Inc.'s Chief Technology Officer, Raymond Woo, reported an open-market sale of 705 shares of common stock at $19.79 per share. The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units. Following this transaction, Woo directly holds 166,912 shares of Ceribell common stock.
[Form 4] Ceribell, Inc. Insider Trading Activity
Ceribell, Inc.'s Chief Revenue Officer, Joseph S. Manni, reported an open-market sale of 768 shares of common stock on February 23, 2026, at $19.79 per share. This sale was conducted to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs). Following this transaction, Manni directly holds 26,933 shares, which includes 300 shares acquired through the company’s Employee Stock Purchase Plan.
CeriBell (CBLL) Revenue Growth To US$24.8m Tests Premium Valuation Narrative
CeriBell (CBLL) closed FY 2025 with Q4 revenue of US$24.8 million and a basic EPS loss of US$0.36, bringing trailing 12-month revenue to US$89.1 million and a net loss of US$53.4 million. The company's valuation, at a P/S of 7.9x compared to an industry average of 3x, is considered premium due to its growth potential in acute care EEG, despite ongoing losses and no short-term path to profitability. This scenario creates a mixed narrative for investors, balancing strong revenue growth against significant losses and a high valuation.
Top Ceribell Executives Quietly Unload Shares in Coordinated Insider Move
Top executives at Ceribell, Inc. (CBLL) recently sold shares, with CEO Xingjuan Chao, SVP of Finance David Foehr, and CTO Raymond Woo conducting significant sales on February 25, 2026. This insider selling occurred shortly after Ceribell announced strong Q4 revenue, projected 2025 as a milestone year with expanded opportunities, and hinted at 25%-29% revenue growth for 2026 despite conservative guidance. TipRanks' AI Analyst, Spark, rates CBLL as "Neutral" due to strong growth and high gross margins being offset by persistent losses and cash burn.
Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
Ceribell, Inc. reported strong financial results for the fourth quarter and full year ended December 31, 2025, with total revenue increasing by 34% and 36% respectively compared to the prior year. The medical technology company achieved significant milestones, including FDA clearances for continuous monitoring solutions and seizure detection algorithms, and received Breakthrough Device Designation for LVO stroke detection. Ceribell projects continued growth for 2026, with an anticipated revenue range of $111 million to $115 million.
CeriBell Q4 Revenue Rises 34%; Projects Revenue Growth Of 25%-29% For FY'26
CeriBell, Inc. reported a 34% increase in Q4 2025 revenue to $24.78 million and a 36% rise in full-year 2025 revenue to $89.06 million, primarily due to new account expansion and adoption growth. Despite widened net losses, the medical technology company projects full-year 2026 revenue to grow by 25% to 29%, estimating $111 million to $115 million, driven by recent FDA clearances for its Ceribell System technologies for seizure detection, delirium monitoring, and LVO stroke detection.
Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
Ceribell announced its financial results for the fourth quarter and full year ended December 31, 2025, reporting significant revenue growth of 34% and 36% respectively compared to the previous year. The company achieved key regulatory milestones, including FDA clearances for continuous monitoring solutions and an expanded seizure detection algorithm for neonates, and received Breakthrough Device Designation for a stroke detection solution, positioning it for continued market expansion. For 2026, Ceribell projects revenues between $111 million and $115 million, reflecting a 25% to 29% growth.
Ceribell Inc (NASDAQ:CBLL) Reports Strong Q4 Revenue Beat and Provides 2026 Outlook
Ceribell Inc. (NASDAQ:CBLL) announced strong Q4 2025 financial results, beating revenue expectations with $24.8 million, a 34% increase year-over-year, alongside a narrower-than-expected net loss per share. The medical technology firm also provided a 2026 revenue outlook of $111 million to $115 million, reflecting continued growth. Despite accelerating losses for the full year due to growth investments, the company highlighted significant operational and regulatory milestones, including new FDA clearances and a solid cash position to fund future expansion.
CeriBell Q4 Revenue Rises 34%; Projects Revenue Growth Of 25%-29% For FY'26
CeriBell, Inc. (CBLL) reported a significant increase in revenue for the fourth quarter and full year of 2025, with Q4 revenue rising 34% to $24.78 million and full-year revenue up 36% to $89.06 million, primarily due to new account expansion and adoption growth. Despite wider net losses for both periods, the company provided strong guidance for full-year 2026, projecting revenue growth of 25% to 29%, estimating $111 million to $115 million. CeriBell also highlighted recent FDA clearances and designations for its medical technology, including its Clarity algorithm for seizure detection and solutions for delirium monitoring and LVO stroke detection.
Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
Ceribell, Inc. announced strong financial results for Q4 and the full year 2025, reporting significant revenue growth of 34% and 36% respectively, driven by expanded account adoption. The company also achieved key regulatory milestones, including FDA clearances for delirium monitoring and pediatric/neonatal seizure detection, and a Breakthrough Device Designation for stroke detection. Looking ahead, Ceribell projects 2026 revenue between $111 million and $115 million.
Ceribell, Inc. SEC 10-K Report
Ceribell, Inc. has released its annual 10-K report for the fiscal year ending December 31, 2025, detailing significant financial growth with total revenue of $89.1 million and product expansion, including FDA clearance for a delirium monitoring solution. Despite a net loss of $(53.4) million, the company is focusing on market expansion, R&D, and capital management, aiming to establish its Ceribell System as the standard of care in acute EEG while navigating operational, financial, market, regulatory, and macroeconomic risks.
